Programmable Medicine is a clinical stage company with a transformative nanomedicine technology exclusively licensed from Johns Hopkins University. The nanomedicine, hydroxyl dendrimers (HDs), precisely target activated inflammatory cells anywhere in the body. HD therapeutics (HDTs) are a new drug class (NCEs) that have demonstrated excellent safety in 5 Phase 1 trials and 3 Phase 2 trials. Each product asset resides in an individual C-corporation: 1) Ashvattha (ophthalmology): at-home administered monthly subcutaneous nanomedicine (Phase 2 results in wet AMD and DME patients); 2) IronFist (radio-oncology): 177Lu nanomedicine selectively targets TAMs (Preclinical POC, Phase 1/2 2H 2026); NanoPower (autoimmune): anti-inflammatory nanomedicine (published Phase 2; Phase 2 in ME/CFS 2H 2026). ENIAC (Neuro-imaging): 18F nanomedicine selectively targeting activated microglia (Phase 2 POC in PPMS; Phase 2 AD, MS ongoing). Additional nanomedicines include JAK, Tyk2, and CSF1R inhibitors.